"Amyloidosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
| Descriptor ID |
D000686
|
| MeSH Number(s) |
C18.452.845.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Amyloidosis".
Below are MeSH descriptors whose meaning is more specific than "Amyloidosis".
This graph shows the total number of publications written about "Amyloidosis" by people in this website by year, and whether "Amyloidosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amyloidosis" by people in Profiles.
-
Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. The amyloid-? pathway in Alzheimer's disease: a plain language summary. Neurodegener Dis Manag. 2023 06; 13(3):141-149.
-
Ream S, Ma J, Rodriguez T, Sarabia-Gonzalez A, Alvarado LA, Dwivedi AK, Mukherjee D. Ethnic/racial differences in risk factors and clinical outcomes among patients with amyloidosis. Am J Med Sci. 2023 03; 365(3):232-241.
-
Henr?quez G, M?ndez L, Casta?eda E, Wagler A, Jeon S, Narayan M. Preclinical Model to Evaluate Outcomes of Amyloid Cross-Toxicity in the Rodent Brain. ACS Chem Neurosci. 2022 10 19; 13(20):2962-2973.
-
Inyushin M, Zayas-Santiago A, Rojas L, Kucheryavykh L. On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications. Front Immunol. 2020; 11:571083.
-
Henriquez G, Mendez L, Narayan M. A Hybrid Model to Study Amyloid Cross-Toxicity. ACS Chem Neurosci. 2020 02 05; 11(3):228-230.
-
Sreenivasan S, Narayan M. Learnings from Protein Folding Projected onto Amyloid Misfolding. ACS Chem Neurosci. 2019 09 18; 10(9):3911-3913.
-
Yadav A, Garg T, Mandal AK, Chander R. Quality of life in patients with acquired pigmentation: An observational study. J Cosmet Dermatol. 2018 12; 17(6):1293-1294.
-
Watanabe K, Uchida K, Chambers JK, Ushio N, Nakayama H. Deposition, Clearance, and Reinduction of Amyloid A Amyloid in Interleukin 1 Receptor Antagonist Knockout Mice. Vet Pathol. 2017 01; 54(1):99-110.
-
Fujita T, Ichikawa S, Okitsu Y, Fukuhara N, Yoshinaga T, Yazaki M, Harigae H. Primary AL amyloidosis presenting with systemic lymphadenopathy with calcification. Int J Hematol. 2016 Dec; 104(6):641-643.
-
Manral P, Reixach N. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Biosci Rep. 2015 Jan 14; 35(1).